氟比洛芬用于治疗转移性乳腺癌患者的骨痛。

Flurbiprofen for the treatment of bone pain in patients with metastatic breast cancer.

作者信息

Lomen P L, Samal B A, Lamborn K R, Sattler L P, Crampton S L

出版信息

Am J Med. 1986 Mar 24;80(3A):83-7. doi: 10.1016/0002-9343(86)90118-x.

Abstract

Two investigators enrolled 26 women with metastatic breast carcinoma in a six-week, double-blind, placebo-controlled, crossover study of flurbiprofen (Ansaid, Upjohn) and placebo. The study was designed to determine the efficacy of flurbiprofen in reducing bone pain due to metastatic breast cancer. Pain score, overall performance, and concomitant use of narcotics were evaluated. The overall mean differences in pain scores between flurbiprofen and placebo showed better control of pain during treatment with flurbiprofen. None of these differences approached statistical significance. Evaluation of overall performance status reached statistical significance in one investigator's group. Three out of four patients reported decreased consumption of acetaminophen/aspirin plus codeine combinations while receiving flurbiprofen.

摘要

两名研究人员招募了26名转移性乳腺癌女性患者，进行了一项为期六周的双盲、安慰剂对照、交叉试验，研究氟比洛芬（安赛蜜，优普强公司生产）和安慰剂。该研究旨在确定氟比洛芬在减轻转移性乳腺癌引起的骨痛方面的疗效。评估了疼痛评分、总体表现以及麻醉药品的联合使用情况。氟比洛芬和安慰剂之间疼痛评分的总体平均差异表明，在使用氟比洛芬治疗期间对疼痛的控制更好。这些差异均未达到统计学显著性。在一名研究人员的小组中，对总体表现状态的评估达到了统计学显著性。四名患者中有三名报告在服用氟比洛芬期间对乙酰氨基酚/阿司匹林加可待因组合的消耗量减少。